Skip to main content
Premium Trial:

Request an Annual Quote

NextBio, Sanofi Collaborate on Translating Molecular Data

NEW YORK (GenomeWeb News) – NextBio today announced it has forged a multiyear deal with Sanofi for use of the NextBio Clinical platform in the drug manufacturer's R&D work.

Sanofi will use the platform for aggregating, standardizing, and analyzing patient clinical data, next generation sequencing, and other molecular data across public data sources, Sanofi's clinical trials, and Sanofi's hospital partners, NextBio said. Sanofi is using the NextBio Clinical platform as part of its Translational Medicine for Patients program.

NextBio said that the system will allow Sanofi to leverage a vast and growing pool of patient data for translational and clinical research.

"The new translational medicine partnership with NextBio, with its big data genomics capabilities, will enable Sanofi to implement patient-centered approaches across all stages of translational and clinical research in several major therapeutic areas, including oncology and diabetes," NextBio President and CEO Saeid Akhtari said in a statement.

Financial and other terms of the deal were not disclosed.

The Scan

Booster for Kids

The US Food and Drug Administration has authorized a booster dose of Pfizer-BioNTech's SARS-CoV-2 vaccine for 5-to-11-year olds, the Washington Post reports.

Novavax Anticipates Authorization

Novavax expects to receive US Food and Drug Administration authorization for vaccine soon, according to CNBC.

Some Old Microbes Indeed

Vice reports that researchers may have uncovered 830-million-year-old microbes.

PNAS Papers on Meiotic Crossover, RNA Targeting, SNAT7 mTORC1 Regulation

In PNAS this week: meiotic crossover formation in C. elegans, approach to identify small molecules affecting RNA activity, and more.